Luminex to Acquire Tm Bioscience; Hopes to Move Its Reagents to Broader Markets | GenomeWeb
NEW YORK (GenomeWeb News) — Luminex today said it plans to acquire Canadian molecular diagnostic company Tm Bioscience in a stock-for-stock deal.
 
Luminex said it plans to use what it calls Tm’s “strong menu of kits and reagents” with its own business connections to enhance its sales by getting Tm’s products to wider markets.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.